Here’s a rapid-fire update on all 36 stocks in our portfolio, including our latest addition
[ad_1] Jim Cramer ran through the names during the Club’s October Monthly Meeting on Wednesday. [ad_2] Source link
Jim Cramer
Read More
Jim Cramer praises Walgreens new CEO pick, says buy the stock ‘perhaps aggressively’
[ad_1] CNBC’s Jim Cramer on Wednesday praised the incoming CEO of Walgreens Boots Alliance, saying industry veteran Tim Wentworth is the right choice to lead the struggling pharmacy chain in its transition to offering more health-care services. “This guy is the real deal. I just salute him and think he can take you to a…
15 stocks with a history of dividend growth are expected to deliver once again this year
[ad_1] Broadcom (AVGO), Caterpillar (CAT) and Eli Lilly (LLY) are among the 15 Club stocks with a streak of annual dividend growth that Wall Street expects to continue in their current fiscal years. Long-term investors should look to own companies with a history of dividend growth instead of chasing stocks with high yields, Morgan Stanley…
Cramer says Vertex has a drug that may address the ‘largest market opportunity in the world’
[ad_1] CNBC’s Jim Cramer on Monday suggested that investors keep an eye on Vertex Pharmaceuticals (VRTX), a biotechnology company developing a drug to treat acute pain that is not an opioid. “The biggest pharmacy issue [is] how do we get pain removed, or at least nullified, without opiates? They have a plan — Vertex,” Cramer…
Here are all the portfolio moves the Club made in this week’s oversold market
[ad_1] With the stock market deeply oversold this week, we put cash to work by picking stocks across a range of sectors including energy, technology and materials. We also added a former Club chipmaker to our Bullpen and upgraded a premium beer name to a buy rating. Finally, Friday’s market reversal helped us make good…
We’re booking some profits on this health insurance stock after waiting out its slump
[ad_1] It’s taken some patience. But shares of this company finally broke through $500 each in Friday trading, so we’re ringing the register. [ad_2] Source link
It’s time to get bullish on this health tech name, now that it’s shed a drag on growth
[ad_1] We care much more about where a stock is going than where it’s been. With the spin-off of Veralto (VLTO) complete, we decided to look at the path ahead for Danaher (DHR) — now free of its slower-growing, lower-margin water business. In the separation , we decided to keep the 173 shares of Veralto…
We’re set to receive shares in Danaher’s separated water business. Here’s our plan for the new stock
[ad_1] Danaher (DHR) is a day away from shedding its environmental-and-applied solutions segment, and the Club holding’s ability to deliver returns for shareholders appears stronger than ever. Those potential returns can come from two places: Danaher stock and shares of Veralto (VLTO), the soon-to-be-standalone company that’s in the business of water quality. We see underappreciated…
Health care has had a tough year. Where we stand on our 5 stocks in the sector
[ad_1] There’s Eli Lilly (LLY), and then there’s everybody else. That’s a simple way to describe the performance of the Club’s health-care holdings so far this year, in what’s been a challenging period for the industry overall. Of the 11 market sectors year to date, health care is the fourth worth-worst performer, falling 4%, followed…
Here’s a rapid-fire update on all 35 stocks in the Club’s portfolio, including a new buy
[ad_1] Jim Cramer ran through all 35 Club stocks during our September Monthly Meeting on Thursday. [ad_2] Source link